Academic Bibliography

Show Sort by

Your filters: cql: author exact 001999384915 cql: author exact 801001466979

Mark
Standardized added metabolic activity (SAM) IN 18F-FDG PET assessment of treatment response in colorectal liver metastases

Jeroen Mertens (UGent) , SYLVIE DE BRUYNE (UGent) , Nancy Van Damme (UGent) , Peter Smeets (UGent) , Wim Ceelen (UGent) , Roberto Troisi (UGent) , Stéphanie Laurent (UGent) , Karen Geboes (UGent) , Marc Peeters (UGent) , Ingeborg Goethals (UGent) , et al.

(2013) EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 40(8). p.1214-1222
Mark
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases

SYLVIE DE BRUYNE (UGent) , Nancy Van Damme (UGent) , Peter Smeets (UGent) , Liesbeth Ferdinande (UGent) , Wim Ceelen (UGent) , Jeroen Mertens (UGent) , Christophe Van De Wiele (UGent) , Roberto Troisi (UGent) , Louis Libbrecht (UGent) , Stéphanie Laurent (UGent) , et al.

(2012) BRITISH JOURNAL OF CANCER. 106(12). p.1926-1933
Mark
- conference
- C3
- open access
FDG-PET is a predictor of metabolic response to chemotherapy in metastatic colorectal cancer (mCRC)

Nancy Van Damme (UGent) , SYLVIE DE BRUYNE (UGent) , Jeroen Mertens (UGent) , Christophe Van De Wiele (UGent) , Wim Ceelen (UGent) , Peter Smeets (UGent) , Liesbeth Ferdinande (UGent) , Stéphanie Laurent (UGent) , Karen Geboes (UGent) and Marc Peeters (UGent)

(2011) JOURNAL OF CLINICAL ONCOLOGY. 29(15, suppl.).
Mark
- conference
- C3
An evaluation of FDG-PET as a predictor of metabolic response to chemotherapy in metastatic colorectal cancer patients (mCRC)

Nancy Van Damme (UGent) , SYLVIE DE BRUYNE (UGent) , Jeroen Mertens (UGent) , Christophe Van De Wiele (UGent) , Wim Ceelen (UGent) , Peter Smeets (UGent) , Liesbeth Ferdinande (UGent) , Stéphanie Laurent (UGent) , Karen Geboes (UGent) and Marc Peeters (UGent)

(2011) JOURNAL OF CLINICAL ONCOLOGY. 29(15, suppl.).
Mark
- conference
- C3
- open access
PET as a predictor of metabolic response to antiangiogenic therapy in metastatic colorectal cancer (mCRC)

Nancy Van Damme (UGent) , SYLVIE DE BRUYNE (UGent) , Liesbeth Ferdinande (UGent) , Wim Ceelen (UGent) , Jeroen Mertens (UGent) , Christophe Van De Wiele (UGent) , Stéphanie Laurent (UGent) , Peter Smeets (UGent) , Karen Geboes (UGent) and Marc Peeters (UGent)

(2011) ANNALS OF ONCOLOGY. 22(suppl. 5). p.V92-V92
Mark
- conference
- C3
- open access
Preoperative chemotherapy for colorectal liver metastases : prediction of response by DCE-MRI abd FDG-PET/CT?

SYLVIE DE BRUYNE (UGent) , Peter Smeets (UGent) , Nancy Van Damme (UGent) , Wim Ceelen (UGent) , Christophe Van De Wiele (UGent) , Stéphanie Laurent (UGent) , Karen Geboes (UGent) , Jeroen Mertens (UGent) and Marc Peeters (UGent)

(2011) EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 38(suppl. 2). p.S195-S195

Academic Bibliography

Standardized added metabolic activity (SAM) IN 18F-FDG PET assessment of treatment response in colorectal liver metastases

Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases

FDG-PET is a predictor of metabolic response to chemotherapy in metastatic colorectal cancer (mCRC)

An evaluation of FDG-PET as a predictor of metabolic response to chemotherapy in metastatic colorectal cancer patients (mCRC)

PET as a predictor of metabolic response to antiangiogenic therapy in metastatic colorectal cancer (mCRC)

Preoperative chemotherapy for colorectal liver metastases : prediction of response by DCE-MRI abd FDG-PET/CT?

Contents

Support

Contact